Two doses of daclizumab are sufficient for prolonged interleukin-2Rα chain blockade

Transplantation

Volumn 72, Issue 10, 2001, Pages 1709-1710

  Ter Meulen, C G ^a   Baan, C C ^a   Hene R J ^a   Hilbrands, L B ^a   Hoitsma, A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECEPTOR SUBUNIT; TACROLIMUS;

DOSE RESPONSE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0035960661     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200111270-00027     Document Type: Letter

References (5)

1. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
2. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody
3. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
4. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation
5. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients